These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 15077223

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, Baxter-Lowe L, Satwani P, George D, Bradley MB, Garvin J, Cairo MS.
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H, Liu KY, Liu DH, Xu LP, Han W, Chen YH, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2008 Aug 05; 88(30):2127-30. PubMed ID: 19080474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM, Goyal RK, Joshi R, Kenkre TS, Howrie D, Venkataramanan R.
    Biol Blood Marrow Transplant; 2016 Apr 05; 22(4):682-689. PubMed ID: 26740371
    [Abstract] [Full Text] [Related]

  • 8. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun 05; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 9. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G.
    Bone Marrow Transplant; 2005 Jun 05; 35(11):1089-93. PubMed ID: 15821769
    [Abstract] [Full Text] [Related]

  • 10. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep 05; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 11. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P, Bhatia M, Garvin JH, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.
    Biol Blood Marrow Transplant; 2012 Feb 05; 18(2):324-9. PubMed ID: 22079471
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone.
    Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, Yamamoto H, Kato D, Matsuno N, Masuoka K, Araoka H, Asano-Mori Y, Izutsu K, Makino S, Yoneyama A, Taniguchi S.
    Transplantation; 2011 Aug 15; 92(3):366-71. PubMed ID: 21677598
    [Abstract] [Full Text] [Related]

  • 13. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T, Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Sasabe M, Kishimoto T, Inoue A, Kawa K.
    Rinsho Ketsueki; 2000 May 15; 41(5):430-6. PubMed ID: 10879106
    [Abstract] [Full Text] [Related]

  • 14. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.
    Biol Blood Marrow Transplant; 2019 Jan 15; 25(1):73-85. PubMed ID: 30153491
    [Abstract] [Full Text] [Related]

  • 15. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S, Ponce DM, Hilden P, Zheng J, Devlin SM, Lubin M, Pozotrigo M, Mathew S, Adel N, Kernan NA, O'Reilly R, Prockop S, Scaradavou A, Hanash A, Jenq R, van den Brink M, Giralt S, Perales MA, Young JW, Barker JN.
    Biol Blood Marrow Transplant; 2015 May 15; 21(5):920-5. PubMed ID: 25687796
    [Abstract] [Full Text] [Related]

  • 16. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar 15; 24(3):129-33. PubMed ID: 12697123
    [Abstract] [Full Text] [Related]

  • 17. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, Tamaki H, Inoue T, Hasei H, Iiboshi Y, Tazuke Y, Kawakami M, Kim EH, Soma T, Inoue T, Kawase I.
    Exp Hematol; 2008 Jan 15; 36(1):1-8. PubMed ID: 17920757
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
    Zohren F, Schroeder T, Czibere A, Fenk R, Bruns I, Kondakci M, Saure C, Haas R, Kobbe G.
    Bone Marrow Transplant; 2011 May 15; 46(5):747-55. PubMed ID: 20661230
    [Abstract] [Full Text] [Related]

  • 19. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL, Valcárcel D, Fernández-Avilés F, Martino R, Rovira M, Barba P, Martínez C, Brunet S, Sureda A, Carreras E, Sierra J.
    Bone Marrow Transplant; 2010 Sep 15; 45(9):1449-56. PubMed ID: 20140024
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.